2021
Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms
Weininger G, Chan SM, Zafar M, Ziganshin BA, Elefteriades JA. Risk reduction and pharmacological strategies to prevent progression of aortic aneurysms. Expert Review Of Cardiovascular Therapy 2021, 19: 619-631. PMID: 34102944, DOI: 10.1080/14779072.2021.1940958.Peer-Reviewed Original ResearchConceptsAortic aneurysmAbdominal aortic aneurysmß-blockersAngiotensin II receptor blockersAngiotensin-converting enzyme inhibitorAnti-platelet medicationDifferent pharmacologic therapiesII receptor blockersAortic aneurysm patientsThoracic aortic aneurysmRisk reductionAortic aneurysm growthPharmacologic managementReceptor blockersPharmacologic therapyMedical therapySurgical interventionAneurysm patientsMiscellaneous drugsAneurysm diseasePharmacological strategiesSyndrome patientsMarfan syndromeEnzyme inhibitorsAneurysms
2018
Chapter 3 Histology of Aortic Disease and Progression of Aortic Dissection From Acute to Chronic
Zafar M, Peterss S, Ziganshin B, Elefteriades J. Chapter 3 Histology of Aortic Disease and Progression of Aortic Dissection From Acute to Chronic. 2018, 41-59. DOI: 10.1016/b978-0-12-809979-7.00003-1.Peer-Reviewed Original ResearchChronic stateUncomplicated acute type B dissectionAcute type B dissectionAcute Stanford typeType B dissectionEarly surgical interventionTreatment of choiceChronic dissectionB dissectionStanford typeAortic dissectionMedical therapyAortic diseaseSurgical interventionDissectionAortaTemporal courseHistologyMorphological changesAcuteChronicHistopathologyTherapyDiseaseProgression